ARTICLE | Emerging Company Profile
Clasp: Optimizing T cell engagers for tighter binding, more cancer killing
Launched in March with $150M, Clasp is designing T cell-engaging bispecifics to better fit the immune synapse
July 18, 2024 4:43 PM UTC
Clasp is designing bispecifics that recreate the native TCR immune synapse for optimal activity against peptide-HLA complexes. The idea is to engineer tight binding between a cancer antigen displayed by an HLA molecule and a cytotoxic T cell to ensure the tumor’s destruction.
With technology out of Johns Hopkins University, and incubated by Catalio Capital Management and Third Rock Ventures, Clasp Therapeutics Inc. announced a $150 million series A round in March. Novo Holdings joined Catalio and Third Rock in the round...